100 terminated. 100 Phase 3, 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 100 | Terminated 100 |
| Phase 2 | 14 | Terminated 14 |
Follow Neurocognitive Disorders: new trials by email Literature Review of Neurocognitive Disorders trials Research Report on Neurocognitive Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Study to Assess the Long-term Safety of AXS-05 in Subjects With Dementia of the Alzheimer's Type, ADVANCE-2 and ACCORD-2 Extension Study AXS-05 (dextromethorphan-bupropion) - Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease | Phase 3 | Terminated | Axsome Therapeutics, Inc. | 139 | 2024-11-21 | 2026-06-25 |
| Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects Experimental: ALZ-801 - Early Alzheimer's Disease | Phase 3 | Terminated | Alzheon Inc. | 163 | 2024-04-02 | 2026-06-25 |
| Continuation Study for Latozinemab Latozinemab - Neurodegenerative Diseases | Phase 3 | Terminated | Alector Inc. | 17 | 2023-12-08 | 2026-01-21 |
| AGItated Patients Management: intraNASAL Midazolam vs Intramuscular Loxapine Intranasal midazolam, Intramuscular loxapine - Emergence Delirium | Phase 3 | Terminated | Assistance Publique - Hôpitaux de Paris | 1 | 2023-04-09 | 2024-05-28 |
| A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease SAGE-718 - Huntington's Disease | Phase 3 | Terminated | Supernus Pharmaceuticals, Inc. | 153 | 2022-12-14 | 2025-12-17 |
| Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) BXCL501, Matching Placebo - Agitation, Dementia | Phase 3 | Terminated | BioXcel Therapeutics Inc | 13 | 2022-12-05 | 2026-10-01 |
| Open-label Extension for Phase 3 Clinical Trials of Simufilam Simufilam - Alzheimer Disease | Phase 3 | Terminated | Cassava Sciences, Inc. | 1081 | 2022-11-07 | 2025-05-23 |
| Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease Piromelatine 20 mg, Placebo - Alzheimer's Disease | Phase 2 / Phase 3 | Terminated | Neurim Pharmaceuticals Ltd. | 216 | 2022-06-15 | 2026-09-09 |
| A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease Aducanumab, Placebo - Alzheimer's Disease | Phase 3 | Terminated | Biogen | 1027 | 2022-06-02 | 2025-04-23 |
| A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) Gantenerumab, Placebo - Alzheimers Disease | Phase 3 | Terminated | Hoffmann-La Roche | 25 | 2022-04-19 | 2025-06-12 |
| GM1 Prophylaxis for Post-chemotherapy Cognitive Impairment in Patients With Early Operable Breast Cancer Ganglioside-Monosialic Acid, 250ml normal saline (NS) - Chemotherapy-Related Cognitive Impairment, Breast Cancer | Phase 3 | Terminated | Sun Yat-sen University | 76 | 2022-02-08 | 2024-08-01 |
| A Lithium-Based Medication to Improve Neurological Outcomes After Surgical Carotid Reconstruction Lithium Carbonate, Placebo - Carotid Artery Diseases, Carotid Artery Stenosis | Phase 3 | Terminated | Negovsky Reanimatology Research Institute | 107 | 2021-11-20 | 2025-09-25 |
| Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease Simufilam, Placebo - Alzheimer Disease | Phase 3 | Terminated | Cassava Sciences, Inc. | 1125 | 2021-11-18 | 2025-09-22 |
| Assessing the Role of Cariprazine in Improving Cognition in Euthymic Bipolar Patients Cariprazine, Placebo - Bipolar I Disorder, Cognitive Impairment | Phase 3 | Terminated | Lakshmi N Yatham | 1 | 2021-07-07 | 2024-10-26 |
| Open Label Study of ATH-1017 for Treatment of Mild to Moderate Alzheimer's Disease ATH-1017 - Alzheimer Disease | Phase 2 / Phase 3 | Terminated | LeonaBio | 423 | 2021-06-30 | 2025-04-01 |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Long-Term Gantenerumab Administration in Participants With Alzheimer's Disease (AD) Gantenerumab - Alzheimer Disease | Phase 3 | Terminated | Hoffmann-La Roche | 1382 | 2021-01-26 | 2024-05-08 |
| Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type AVP-786, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 241 | 2020-09-11 | 2025-05-30 |
| A Phase 3 Study to Evaluate Efficacy and Safety of AL001 in Frontotemporal Dementia (INFRONT-3) Part 1 Blinded - AL001, Part 1 Blinded - Placebo, Part 2 (OLE Treatment) - AL001 - Frontotemporal Dementia | Phase 3 | Terminated | Alector Inc. | 119 | 2020-07-23 | 2026-09-21 |
| Assessment of the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type AVP-786, Placebo - Agitation in Patients With Dementia of the Alzheimer's Type | Phase 3 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 184 | 2020-07-13 | 2025-05-30 |
| Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation Gantenerumab - Alzheimers Disease, Dementia | Phase 2 / Phase 3 | Terminated | Washington University School of Medicine | 73 | 2020-06-03 | 2025-02-04 |
Showing 20 of 100. Sign in to see all of them.
Alzheimer Disease (65) · Dementia (26) · Cognitive Dysfunction (16) · Delirium (10) · Nervous System Diseases (7) · Central Nervous System Diseases (6) · Mental Disorders (6) · Neurodegenerative Diseases (6) · Psychomotor Agitation (6) · Brain Diseases (5) · Tauopathies (5) · Emergence Delirium (4) · Huntington Disease (4) · Frontotemporal Dementia (3)
Mental Disorders (94) · Nervous System Diseases (87) · Brain Diseases (77) · Central Nervous System Diseases (76) · Neurodegenerative Diseases (67) · Tauopathies (60) · Dementia (53) · Pathological Conditions, Signs and Symptoms (24) · Cognition Disorders (23) · Neurologic Manifestations (23) · Signs and Symptoms (23) · Neurobehavioral Manifestations (21) · Confusion (12) · Dyskinesias (10)
Haloperidol (6) · gantenerumab (6) · Memantine (5) · bapineuzumab (5) · latrepirdine (5) · Donepezil (4) · aducanumab (4) · 7-chloro-N-quinuclidin-3-yl-benzo(b)thiophene-2-carboxamide (3) · Dexmedetomidine (3) · Quetiapine Fumarate (3) · Rivastigmine (3) · crenezumab (3) · lanabecestat (3) · solanezumab (3) · 3-benzenesulfonyl-8-piperazin-1-ylquinoline (2)
Hoffmann-La Roche (8) · Pfizer (8) · Biogen (4) · AstraZeneca (3) · Eli Lilly and Company (3) · FORUM Pharmaceuticals Inc (3) · Merck Sharp & Dohme LLC (3) · Alector Inc. (2) · Axovant Sciences Ltd. (2) · Cassava Sciences, Inc. (2) · Eisai Inc. (2) · GlaxoSmithKline (2) · H. Lundbeck A/S (2) · Janssen Research & Development, LLC (2) · M. Schaefer, MD (2)
United States (67) · Canada (53) · Spain (40) · United Kingdom (40) · Australia (37) · Germany (37) · France (34) · Italy (30) · Poland (26) · South Korea (26) · Netherlands (25) · Belgium (24) · Japan (24) · Sweden (21) · Portugal (18)
Ilise Lombardo, MD (2) · James Kupiec, MD (2) · Mark Laughlin, MD (2) · Martin Schaefer, MD (2) · Thomas McRae, MD (2) · Aaron H Burstein, PharmD (1) · Almudena Garnica, MD (1) · Amanda G Smith, MD (1)
PMID 40603145, PMID 39556389, PMID 41537338, PMID 42841310, PMID 26297092, PMID 27176461, PMID 27334799, PMID 27767991, PMID 27807285, PMID 31390660, PMID 31764959, PMID 33049114, PMID 34807243, PMID 35384522, PMID 35747889, PMID 36121669, PMID 36600109, PMID 36641609, PMID 37966285, PMID 38165296, PMID 39498781, PMID 39887500, PMID 40302041, PMID 42598748, PMID 18041437, PMID 18378947, PMID 23472619, PMID 23926422, PMID 24591834, PMID 27846868, PMID 27913695, PMID 28701493, PMID 29365294, PMID 29719179, PMID 30103342, PMID 30850442, PMID 30970186, PMID 31387606, PMID 32967873, PMID 33252075, PMID 33253354, PMID 33464300, PMID 35794343, PMID 35897078, PMID 36744336, PMID 36946603, PMID 37904241, PMID 38087949, PMID 38599894, PMID 38940656
2015 (7), 2016 (6), 2017 (3), 2023 (3), 1UF1AG046150-01 (1), 2009 (1), 2014 (1), 2019 (1), K23HL078760 (1), R01AG046179 (1), R01AG053267 (1), R01NS052619 (1), R56AG053267 (1), U01AG042791 (1), U01AG059798 (1)